Gaining a better understanding of the immune cell subsets and molecular factors associated
with protective or pathological immunity against severe acute respiratory syndrome …

COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation,
microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing …

Inflammatory lung diseases represent a persistent burden for patients and the global
healthcare system. The combination of high morbidity,(partially) high mortality and limited …

More than a year has passed since the world began to fight the novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the Coronavirus disease …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been prevalent in the
humans since 2019 and has given rise to a pandemic situation. With the discovery and …

The aim of this study was to investigate the role of molecular mimicry in the cytokine storms
associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Human …

Dexamethasone implementation for COVID-19 management represented a milestone but
data regarding its impact and safety have not been consistently reproduced. We aimed to …

The rapid mutation of the SARS-CoV-2 virus is now a major concern with no effective drugs
and treatments. The severity of the disease is linked to the induction of a cytokine storm that …

The mitogen‐activated protein kinase (MAPK) pathway links the cell‐surface receptors to the
transcription machinery, transducing the extracellular signals into several outputs, which …

Objectives To explore the anti-inflammatory effect and the potential mechanism of
dexmedetomidine in ARDS/ALI. Materials and Methods C57BL/6 mice and EL-4 cells were …